Know Cancer

or
forgot password

A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA


Phase 2
18 Years
75 Years
Open (Enrolling)
Both
Acute Myeloid Leukemia

Thank you

Trial Information

A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA


Inclusion Criteria:



1. Adult men and women subjects aged 18 to 75, inclusive.

2. Confirmed diagnosis of relapsed/refractory AML (WHO criteria) Refractory subjects, up
to second consecutive salvage . Relapsed subjects including first and second relapse.

3. AML relapse > 6 months since autologous or allogeneic stem cell transplantation,
provided they are in first or second relapse and:

No active graft-versus-host disease (GVHD > grade 1). No treatment with high dose
steroids for GVHD (up to 20 mg Prednisolone or equivalent, Appendix G). No treatment
with immunosuppressive drugs with the exception of low dose cyclosporine and
tacrolimus (blood levels of 0.5-0.6 µg/mL).

4. Clinical laboratory values should be as follows:

WBC < 30,000/mL Blasts in PB ≤ 20,000. Treatment with Hydroxyurea is permitted up to
24 hrs prior to BL-8040 administration to achieve blast counts < 20,000 prior to
enrollment. Creatinine < 1.3 mg/dL; if Creatinine is > 1 mg/dL the Creatinine
clearance should be > 40 mL/min as calculated using the Cockcroft-Gault formula.

5. Women of childbearing potential and all men must agree to use an approved form of
contraception (e.g. oral, transdermal patch, implanted contraceptives, intrauterine
device, diaphragm, condom, abstinence or surgical sterility) prior to study entry and
for the duration of study participation through 30 days after the last dose of
BL-8040. Confirmation that female subjects are not pregnant must be established by a
negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test result obtained
during screening. Pregnancy testing is not required for post-menopausal or surgically
sterilized women.

6. Subject is able and willing to comply with the requirements of the protocol.

7. Subject is able to voluntarily provide written informed consent.

Exclusion Criteria:

1. Administration of conventional chemotherapy within 2 weeks of enrollment date. In the
event that subjects have received chemotherapy > 2 weeks from the date of enrollment,
they may be included provided they have recovered from the associated
non-hematological toxicities to ≤ grade 1.

2. Life expectancy of ≤ 2 months.

3. Known allergy or hypersensitivity to any of the test compounds, materials or
contraindication to test product.

4. Use of investigational device or agents within 2 weeks of enrollment date.

5. Low Performance Status (ECOG > 2; Appendix E).

6. O2 saturation < 92% (on room air), evidence of TLS > grade 2 (according to the
Cairo-Bishop criteria (3)) or leukostasis (2).

7. Abnormal liver function tests:

Serum aspartate transaminase (AST/SGOT) or alanine transaminase ( ALT/SGPT) 2 x upper
limit of normal (ULN). Serum bilirubin. Total bilirubin > 2.0 mg/dL (34 µmol/L),
conjugated bilirubin > 0.8 mg/dL.

8. Left ventricular ejection fraction < 40 %.

9. History of myocardial infarction or cerebrovascular accident within 6 months of
enrollment date.

10. Presence of active, uncontrolled infection.

11. Known central nervous system disease (e.g., Alzheimer's disease).

12. Acute promyelocytic leukemia.

13. Exposure to high dose Ara-C within 6 months of enrollment.

14. Subject has concurrent, uncontrolled medical condition, laboratory abnormality, or
psychiatric illness which could place him/her at unacceptable risk, including, but
not limited to:

Subject has been diagnosed or treated for another malignancy within 3 years of
enrolment, except in situ malignancy, or low-risk prostate, skin or cervix cancer
after curative therapy A co-morbid condition which, in the view of the Investigators,
renders the subject at high risk from treatment complications.

15. Female subjects who are pregnant or breastfeeding.

16. Prior clinically significant grade 3-4 non-hematological toxicity to high dose Ara-C
or grade ≥ 2 of neurological toxicity.

17. Seropositive for HIV antibodies (HIV1 and HIV2), Hepatitis C antibody (Hep C Ab) or a
Hepatitis B carrier (positive for Hepatitis B surface antigen [HBsAg]).

18. Unable to comply with study requirements in the opinion of the Investigator.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerability

Outcome Description:

General safety: Vital signs (oral temperature, blood pressure, pulse rate, respiratory rate and O2 saturation), 12-lead ECG and physical examination. Toxicity according to the latest version of NCI-CTCAE (currently V4.03, refer to ) for AEs and clinical laboratory profile as follows: Screening: record and report screening results, however not considered treatment emergent AEs. Throughout the study: record and report all AEs and SAEs according to GCP.

Outcome Time Frame:

"participants will be followed for the duration of hospital stay and the follow up period, an expected average of 6 weeks.

Safety Issue:

Yes

Authority:

United States: Food and Drug Administration

Study ID:

BL-8040.01

NCT ID:

NCT01838395

Start Date:

April 2013

Completion Date:

June 2015

Related Keywords:

  • Acute Myeloid Leukemia
  • AML
  • Acute Myeloid Leukemia
  • Relapsed Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location

MD Anderson Cancer CenterHouston, Texas  77030-4096
Sloan-Kettering Cancer CenterNew York, New York  10065